Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791272 | 0.74 | NOS3 (0.36) | NOS3NOS2NOS1 | |
| SCHEMBL4168479 | 0.73 | MAPK1 (0.33) | — | |
| SCHEMBL9155387 | 0.73 | NOS3 (0.39) | NOS3NOS2NOS1 | |
| SCHEMBL602198 | 0.71 | NOS3 (0.38) | NOS3NOS2LOXL2 | |
| SCHEMBL4199862 | 0.71 | — | — | |
| SCHEMBL1881445 | 0.71 | NOS3 (0.38) | NOS3NOS2LOXL2 | |
| SCHEMBL4177697 | 0.70 | PDE4B (0.30) | — | |
| SCHEMBL790082 | 0.69 | NOS3 (0.36) | NOS3NOS2 | |
| SCHEMBL8010825 | 0.69 | — | — | |
| SCHEMBL1966773 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094705-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-04-18 | — | — | EP | claimed |
| US-8030306-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-04 | — | — | US | claimed |
| US-20100029656-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | claimed |
| CN-101631789-A | Azabicyclic heterocycles as Cannibinoid receptor modulators | BRISTOL MYERS SQUIBB CO | 2010-01-20 | — | — | CN | claimed |
| EP-2094705-A2 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2009-09-02 | — | — | EP | claimed |
| WO-2008076810-A9 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-30 | — | — | WO | claimed |
| WO-2008076810-A2 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-26 | — | — | WO | claimed |
| EP-2094705-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8030306-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100029656-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| CN-101631789-A | Azabicyclic heterocycles as Cannibinoid receptor modulators | BRISTOL MYERS SQUIBB CO | 2010-01-20 | — | — | CN | disclosed |
| WO-2008076810-A9 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029656-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, ARRB1 | NOS3 4390/4885NOS2 3443/4885NOS1 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.